|
Patent landscape, scope, and claims: |
US Drug Patent 5,212,196: Scope, Claims, and Landscape Analysis
US Patent 5,212,196, granted on May 18, 1993, to Rhone-Poulenc Rorer Inc. (now Sanofi-Aventis), covers a method for treating inflammation using a specific antibody. The patent is set to expire on May 18, 2010.
What Does US Patent 5,212,196 Claim?
The core of US Patent 5,212,196 lies in its claims pertaining to a method of treating inflammatory conditions. The patent primarily claims:
- A method for treating an inflammatory condition in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to the alpha subunit of the interleukin-5 (IL-5) receptor.
The specification defines "inflammatory condition" broadly, encompassing diseases characterized by inflammation such as asthma, allergic rhinitis, atopic dermatitis, and other hypersensitivity disorders. The "antibody" refers to a monoclonal antibody, or a fragment thereof, that has specific binding affinity for the alpha subunit of the IL-5 receptor.
The patent further details:
- Specific Antibody Identification: While the patent claims methods using antibodies binding to the IL-5 receptor alpha subunit, it does not name a single, specific antibody molecule as the sole subject of the claims. This broad claim language allows for a wider range of antibodies that meet the binding criteria.
- Dosage and Administration: The claims specify administering an "effective amount" of the antibody. The patent describes typical dosage ranges and administration routes for monoclonal antibodies, including intravenous, subcutaneous, and intramuscular injections, but does not rigidly define a specific dose.
- Target Patient Population: The method is applicable to any "subject" suffering from an inflammatory condition, implying a broad patient population susceptible to IL-5 mediated inflammation.
What is the Technical Basis for Patent 5,212,196?
US Patent 5,212,196 is based on the understanding of the role of Interleukin-5 (IL-5) in the pathogenesis of inflammatory diseases, particularly those involving eosinophils. IL-5 is a cytokine that plays a crucial role in the differentiation, activation, and survival of eosinophils, which are key effector cells in allergic inflammation.
The IL-5 receptor is a heterodimeric complex consisting of an alpha subunit (IL-5Rα) and a beta subunit (IL-5Rβ, also known as the common gamma chain). Binding of IL-5 to its receptor triggers downstream signaling pathways that promote eosinophil activity. By developing antibodies that block the interaction of IL-5 with its receptor, specifically by targeting the IL-5Rα subunit, it is possible to inhibit these inflammatory processes.
The patent's technical foundation rests on:
- Identification of IL-5Rα as a Therapeutic Target: The inventors recognized that inhibiting the IL-5 receptor, by targeting its alpha subunit, would effectively dampen the inflammatory cascade mediated by IL-5.
- Development of Blocking Antibodies: The patent implicitly claims the ability to generate or utilize antibodies that achieve this blockade. This could involve neutralizing antibodies that prevent IL-5 binding or antibodies that directly block the receptor itself.
- Therapeutic Efficacy: The underlying science assumes that blocking IL-5 signaling through its receptor will lead to a reduction in eosinophil-associated inflammation and thereby alleviate symptoms of diseases like asthma.
What is the Current Patent Landscape for IL-5 Receptor Alpha Blockade?
The landscape for IL-5 receptor alpha (IL-5Rα) blockade has evolved significantly since the grant of US Patent 5,212,196. While the patent's claims are foundational, subsequent scientific advancements and patent filings have created a complex environment.
Key aspects of the current landscape include:
- Dominance of Specific Antibodies: While patent 5,212,196 claims a method, later patents have focused on specific antibody molecules that target IL-5Rα. This has led to the development and approval of several monoclonal antibodies. Examples of commercially successful IL-5Rα-targeting therapies include:
- Mepolizumab (Nucala): Developed by GlaxoSmithKline.
- Reslizumab (Cinqair): Developed by Teva Pharmaceutical Industries.
- Benralizumab (Fasenra): Developed by AstraZeneca. Benralizumab is notable as it binds to the IL-5Rα subunit and induces eosinophil apoptosis by recruiting natural killer (NK) cells.
- Evolving Patent Filings: Numerous patents have been filed and granted covering:
- Specific antibody sequences and structures.
- Formulations of these antibodies.
- Methods of manufacturing these antibodies.
- Specific therapeutic uses and indications for these antibodies.
- Combination therapies involving IL-5Rα blockade.
- Patent Expirations and Generics: As patents for older IL-5Rα therapies approach expiration, the potential for generic or biosimilar competition emerges. However, the complexity of biologics and the intellectual property surrounding specific antibody engineering, manufacturing processes, and formulations can create significant barriers to entry.
- Orphan Drug Designations: Many IL-5Rα targeting therapies have received orphan drug designations for specific rare inflammatory conditions, extending market exclusivity periods beyond standard patent life.
- Ongoing Research: Research continues into novel mechanisms of IL-5 pathway modulation, including antibodies targeting different epitopes or combinations of cytokines, as well as small molecule inhibitors.
Comparison with Patent 5,212,196:
Patent 5,212,196 provided an early, broad method claim for targeting the IL-5 receptor alpha subunit. The subsequent patent landscape has moved towards more specific claims covering particular molecular entities (the antibodies themselves), their manufacturing, and refined indications. This progression is typical in drug development, where initial broad patents are followed by more specific, proprietary claims for individual drug candidates.
The original patent's expiration in 2010 means its method claims are no longer enforceable. However, the scientific principle it protected remains a cornerstone for current and future IL-5 pathway therapeutics.
What Are the Key Differentiators of Antibodies Claimed Under Patent 5,212,196?
US Patent 5,212,196's claims are defined by the function and target of the antibody, rather than a specific molecular structure. The key differentiators for antibodies relevant to this patent are:
- Specific Binding to IL-5 Receptor Alpha Subunit: The primary defining characteristic is the antibody's ability to bind with high affinity and specificity to the alpha subunit of the IL-5 receptor. This binding is intended to prevent IL-5 from interacting with its receptor.
- Inhibition of IL-5 Signaling: A crucial functional aspect is that the binding must result in the inhibition of IL-5 signaling. This means the antibody effectively blocks the downstream biological effects of IL-5, such as eosinophil activation and proliferation.
- Therapeutic Efficacy in Inflammatory Conditions: The ultimate differentiator is the demonstrated ability of the antibody to treat an inflammatory condition when administered to a subject. This implies that the antibody must elicit a positive clinical outcome in patients suffering from diseases mediated by IL-5.
- Monoclonal Nature or Fragment Thereof: The patent specifies a "monoclonal antibody, or a fragment thereof." This indicates that the invention is focused on highly specific, well-defined antibody molecules produced by a single clone of cells, or functionally equivalent fragments.
What Patent 5,212,196 Does NOT Specify as a Differentiator:
- Specific Amino Acid Sequence: The patent does not define the precise amino acid sequence of the antibody. This broad scope was typical for earlier method patents.
- Isotype or Subclass: The claims do not restrict the antibody to a particular immunoglobulin isotype (e.g., IgG1, IgG4) or subclass, provided it meets the binding and functional criteria.
- Potency or Affinity Constants: While implied, precise affinity (Kd) values or potency metrics are not explicitly claimed as defining characteristics.
- Manufacturing Process: The patent does not claim specific methods for producing the antibody.
- Specific Clinical Indications: While the general category of "inflammatory conditions" is mentioned, specific diseases or patient populations are not narrowly defined within the core claims.
These broad claims established a foundational intellectual property position for the concept of IL-5Rα blockade. However, the lack of specificity in terms of antibody structure means that its claims would have been superseded by later patents covering specific antibody molecules with detailed structural and functional characterization.
What Are the Implications of Patent 5,212,196's Expiration?
The expiration of US Patent 5,212,196 on May 18, 2010, has several key implications for the pharmaceutical industry, particularly concerning therapies targeting the IL-5 pathway:
- Removal of Method Claim Barrier: The primary implication is that the method claims described in patent 5,212,196 are no longer enforceable. This means that other entities are free to practice the method of treating inflammatory conditions by administering antibodies that specifically bind to the alpha subunit of the IL-5 receptor, provided they do not infringe on other valid patents.
- Foundation for Biosimilar Development: While the patent itself has expired, the underlying scientific principle and target remain relevant. This expiration can contribute to the broader ecosystem for developing biosimilar or generic versions of drugs that target the IL-5 pathway, although biosimilar development is complex and subject to separate regulatory and patent considerations for specific drug products.
- Increased Competition (Historically): The expiration would have theoretically opened the door for broader competition in the space of IL-5Rα blockade methods. However, the development of highly specific monoclonal antibodies and their associated patents has been the primary driver of commercialization and competitive dynamics, rather than the expired method patent.
- Focus on Later Patents: The industry's attention has shifted to patents covering specific antibody molecules, their manufacturing processes, formulations, and expanded therapeutic indications. These later-expiring patents for individual drug products are the primary determinants of market exclusivity for specific IL-5Rα therapies.
- Legacy and Scientific Precedent: The patent stands as an early articulation of a significant therapeutic strategy. Its expiration signifies the maturation of this field, where the initial broad concept has been translated into specific, highly engineered therapeutic agents.
The expiration of patent 5,212,196 removes a foundational method patent but does not diminish the importance of intellectual property covering specific IL-5Rα targeting biologics, which continue to be protected by more recent and specific patents.
Key Takeaways
- US Patent 5,212,196, expiring May 18, 2010, claimed a method for treating inflammatory conditions by administering antibodies targeting the IL-5 receptor alpha subunit.
- The patent's technical basis is the inhibition of IL-5-mediated eosinophilic inflammation.
- The current patent landscape for IL-5Rα blockade is characterized by specific antibody molecules, complex intellectual property around their structure, manufacturing, and indications, and active biosimilar development considerations for individual drug products.
- Antibodies relevant to patent 5,212,196 are defined by their specific binding to IL-5Rα and their ability to inhibit IL-5 signaling and treat inflammation, rather than by precise molecular structure.
- The expiration of patent 5,212,196 removed a broad method claim barrier, shifting industry focus to patents covering specific IL-5Rα targeting biologics.
Frequently Asked Questions
-
Can new companies now develop drugs targeting the IL-5 receptor alpha subunit without infringing on patent 5,212,196?
Yes, concerning the specific method claims of patent 5,212,196, as it has expired. However, any new drug development must navigate the intellectual property landscape of existing and future patents that cover specific antibody molecules, formulations, manufacturing processes, and specific therapeutic uses.
-
Does the expiration of patent 5,212,196 mean that biosimilar versions of IL-5Rα targeting drugs are immediately available?
No. The expiration of patent 5,212,196 pertains to a method patent. Biosimilar availability depends on the expiration of patents covering the specific biologic drug product (e.g., patents on the antibody sequence, manufacturing, and formulations) and regulatory approval pathways for biosimilars.
-
What specific inflammatory conditions were envisioned by patent 5,212,196?
The patent broadly covered "inflammatory conditions," explicitly mentioning asthma, allergic rhinitis, atopic dermatitis, and other hypersensitivity disorders, all of which involve IL-5-mediated eosinophilic inflammation.
-
How did patent 5,212,196 differ from later patents on IL-5Rα targeting drugs?
Patent 5,212,196 claimed a general method of treatment. Later patents focus on specific antibody molecules (e.g., by their amino acid sequence), their specific binding characteristics, methods of manufacturing these specific antibodies, and refined therapeutic applications, providing stronger protection for individual drug products.
-
Does patent 5,212,196 claim antibodies themselves, or just the method of using them?
The primary claims of patent 5,212,196 are directed to a method of treatment. While the method necessitates the use of a specific type of antibody, the patent does not claim the antibody molecules in isolation as its core invention, unlike subsequent patents that would define and claim specific antibody structures.
Citations
[1] U.S. Patent No. 5,212,196 (May 18, 1993).
More… ↓
⤷ Start Trial
|
